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Infectious Diseases
Does treatment of intestinal helminth infections 
influence malaria? Background and methodology 
of a longitudinal study of clinical, parasitological 
and immunological parameters in Nangapanda, 
Flores, Indonesia (ImmunoSPIN Study)
Background: Given t h a t  h e lm in th  in fec t ions  a re  t h o u g h t  t o  h a v e  s t ro n g  i m m u n o m o d u la t o r y  activity, t h e  q u e s t io n  
w h e t h e r  h e lm in th  in fec t ions  m ig h t  affect r e s p o n s e s  to  malaria  a n t ig e n s  n e e d s  t o  b e  a d d re s s e d .  Different c ro ss ­
sec tiona l  s tu d ie s  using  d iverse  m e t h o d o l o g ie s  h a v e  r e p o r t e d  t h a t  h e lm in th  in fec t ions  m ig h t  e i th e r  e x a c e r b a te  or  
r e d u c e  t h e  severi ty  o f  malaria  attacks.  T he  s a m e  d i s c rep a n c ie s  h a v e  b e e n  r e p o r te d  for pa ras i tem ia .  
Methods/Design: To d e t e r m i n e  t h e  e ffec t  o f  g e o h e l m in t h  in fec t ions  a n d  th e i r  t r e a t m e n t  o n  malaria  in fec tion  a n d  
d ise a se  o u t c o m e ,  as well as o n  im m u n o lo g ic a l  p a ra m e te r s ,  t h e  a rea  o f  N a n g a p a n d a  o n  Flores Island, Indonesia ,  
w h e r e  malaria  a n d  h e lm in th  p a ras i tes  a re  c o - e n d e m i c  w a s  se le c te d  for a long itud ina l  study .  Here  a D o u b le -b l in d  
r a n d o m iz e d  trial will b e  p e r fo rm e d ,  in c o rp o ra t in g  r e p e a t e d  t r e a t m e n t  w i th  a lb e n d a z o le  (400 m g)  o r  p l a c e b o  a t  th r e e  
m o n th ly  intervals. H o u s e h o ld  charac te ris t ic  d a ta ,  a n th r o p o m e t r y ,  t h e  p r e s e n c e  o f  intestinal h e lm in th  a n d  Plasmodium  
spp infections,  a n d  t h e  in c id e n c e  o f  malaria  e p i s o d e s  are re co rd e d .  In vitro c u l tu res  o f  w h o le  b lo o d ,  s t im u la te d  w i th  a 
n u m b e r  o f  a n t ig e n s ,  m i t o g e n s  a n d  toll like r e c e p to r  l igands  p ro v id e  re lev an t  im m u n o lo g ic a l  p a r a m e te r s  a t  ba se l ine  
a n d  fo l low ing  1 a n d  2 y ea rs  o f  t r e a t m e n t  ro u n d s .  T h e  pr im ary  o u t c o m e  o f  t h e  s tu d y  is t h e  p r e v a le n c e  o f  Plasmodium  
falciparum  a n d  P. vivax infec tion .  T he  s e c o n d a r y  o u t c o m e  will b e  in c id e n c e  a n d  severi ty  o f  malaria  e p i s o d e s  d e t e c t e d  
via b o th  passive  a n d  active  fo l low -up .  T he  ter t iary  o u t c o m e  is t h e  in f la m m a to ry  cy tok ine  profile in r e s p o n s e  to  
pa ras i te  a n t ig e n s .  T he  p ro jec t  also facili tates t h e  t rans fer  o f  s ta te  o f  t h e  art  m e t h o d o l o g ie s  a n d  te c h n o lo g ie s ,  
m o le c u la r  d iag n o s is  o f  parasit ic  d iseases ,  i m m u n o l o g y  a n d  e p id e m io lo g y  f rom  E urope  to  Indonesia .
Discussion: T h e  s tu d y  will p ro v id e  d a ta  o n  t h e  e ffec t  o f  h e lm in th  in fec t ions  o n  malaria. It will also give 
in fo rm a t io n  o n  a n th e lm in th ic  t r e a t m e n t  efficacy a n d  e f fec t iv en ess  a n d  co u ld  h e lp  d e v e lo p  e v id e n c e - b a s e d  
p o licym aking .
Trial registration: This s tu d y  w a s  a p p r o v e d  b y  T he  Ethical C o m m i t te e  o f  Faculty o f  M edicine,  University  o f  
Indonesia ,  ref:194/PT02.FK/Etik/2006 a n d  has  b e e n  filed by  e th ic s  c o m m i t t e e  o f  t h e  Leiden University  Medical 
C ente r .  Clinical trial number:ISRCTN83830814. T he  s tu d y  is r e p o r t e d  in a c c o r d a n c e  w ith  t h e  CONSORT g u id e l in e s  for 
c lu s te r - r a n d o m iz e d  stud ies .
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Background
Worldwide, more than a billion people are infected by 
geohelminths, with a majority harboring roundworms 
(Ascaris lumbricoides), whipworms (Trichuris trichiura), 
and/or hookworms (Necator americanus or Ancylostoma 
duodenale) [1-3]. Such helminths modify the immune 
system to induce predominant production of T-helper-2 
(Th2) cytokines (interleukin/IL-4, IL-5, IL-9, IL-10, IL- 
13), associated with increased levels of immunoglobulin 
E (IgE) and eosinophilia [4 ,5]. A nother hallmark of 
chronic helminth infections is their ability to induce a 
strong regulatory network characterized by T cell hypor- 
esponsiveness and the increased production of suppres­
sive cytokines such as IL-10 and TGF-b [6]. Their 
ability to induce regulatory responses is thought to be 
advantageous for both the parasite and the host as it 
allows the survival of the parasite for extended periods 
of time within the host while preventing overt patholo­
gical reactions that would otherwise be damaging to the 
host [7]. The latter may explain why such helm inth 
infections rarely result in overt clinical manifestations.
Although the immunological consequences of hel­
m inth infections primarily reflect responses directed 
towards helm inth antigens, there may be spill-over 
effects on responses to unrelated antigens [6,8]. 
W hereas the marked Th2 polarization may compete 
with Th1 cytokines to affect the magnitude of a Th1 
response to an incoming antigen, a strong regulatory 
response can dampen immune reactivity of both Th1 
and Th2 types to a third party antigen. Not surprisingly, 
then, it is argued that helminth infections might modu­
late the human immune response to common co-infec­
tions such as malaria, TB and HIV/AIDS [9-11].
Malaria itself is one of the most serious infectious dis­
eases, infecting 5-10% of the world's population, with 
300-600 million cases and more than 2 million deaths 
annually [12]. In areas of high malaria transmission, the 
burden of disease is borne by infants and young children 
[13,14], whilst, in areas of lower transmission, primary 
infection might also occur later in life, causing severe 
illness [12,15,16].
Co-infection is the norm in nature [9,17], since hel­
minth infections of different species are often endemic 
in the same communities that are exposed to infection 
with plasmodia [18]. The question of whether helminth 
infections affect the course of m alaria has been 
addressed in various reports [19] in the past few years. 
Only a small number of papers report on population 
studies and most of them were cross-sectional in nature, 
which in contrast to longitudinal studies might not be 
able to demonstrate the actual dynamics of infection. 
An early study by Murray and colleagues (1977) in a 
malnourished population at Anjouan, Comoros Islands
suggest that A. lumbricoides might suppress malaria 
symptoms [20]. Since then studies of co-infections have 
shown helminths to either exacerbate [21] or reduce 
[22-24] the severity of malaria. The reasons for conflict­
ing data on the effect of helm inth co-infection on 
malaria disease outcomes could be due to differences in 
study design, study groups, and possibly, most impor­
tantly, the helminth species investigated [18,25].
Although helminth infections are considered as patho­
gens, it is clear that their course of infection is relatively 
free of overt clinical manifestations and in recent years 
several reports have shown their suppressive effect on 
diseases such as allergy [3,26], autoimmunity [27], and 
inflammatory bowel disease [28], highlighting a possible 
beneficial effect on inflammation [29]. To assess the 
influence of helminth infections on inflammatory dis­
eases taking into account environmental and genetic 
influences in a longitudinal setting, the ImmunoSPIN 
project http://www.immunospin.org has been initiated. 
As part of the project ImmunoSPIN, the helm inth- 
malaria sub project (Imm unoSPIN-M alaria) was 
designed to determine whether and how helminth infec­
tions may affect the course of a malaria infection. This 
study is a double-blind randomized trial of placebo and 
anthelminthic treatment to elucidate the impact of hel­
m inth infections on malaria longitudinally in an area 
where helm inth infections and malaria coexist. It is 
expected to provide new information and contribute to 
our understanding of how regulatory responses that may 
be induced by chronic helminth infections affect inflam­
matory conditions, especially on malaria infection.
This paper presents the rationale of the ImmunoSPIN- 
Malaria study that, at the clinical and biological level, 
aims to discern plausible and meaningful interactions 
between these infections.
Methods/Design
Study area and population
Nangapanda is a sub-district of the Ende district, Flores 
Island, Indonesia and is situated in a coastal area with a 
population of about 22000 (Figure 1). Situated near the 
equator (8°45'S, 121°40'E)[30], it is characterized by a 
uniform high temperature, in the range of 23-33.5°C, 
with humidity of 86-95%. Average yearly rain fall is 
1.822 mm with about 82 rainy days, especially from 
November to April, with the peak in December until 
March. Malaria is reported to be highly prevalent in this 
area [31]. Preliminary surveys conducted in 2005 and 
2006 found this area to be endemic for geohelminths 
(A. lum bricoides, hookworms and T. trichiura) and 
malaria parasites (P. falciparum and P. vivax). The sub­
district is divided into villages of which those located 
near the primary health centre (Puskesmas), Ndeturea,
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Ndorurea1, and Ndorurea are the focus of ImmunoS- 
PIN-Malaria study.
The majority in the study area is Ende tribe and 
migrants from neighbouring district of Bajawa that have 
populated the island for more than 300 years. Most indivi­
duals work as farmers and grow their own food. Recently 
also government employees and individuals owning small 
businesses moved to the area. Individuals with Chinese 
and Arabic ethnicity have come to the area about 200 
years ago and most of them, run business corporations 
with other tribes. There are very few other tribes from 
outside of Flores and most of them were brought from 
outside by marriage with Flores natives. The Nangapanda 
population is dynamic and individuals shift address within 
the area as well as move in and out of the area for pur­
poses of studying, marriage, or searching for jobs.
Study design, data and sample collection
Baseline mapping of houses by Global Positioning Sys­
tem (GPS) system has allowed maps to be generated 
using ArcGIS 9,1 software (ESRI, USA). In order to per­
form spatial analyses based on individual data, geogra­
phical coordinates were assigned to each individual as 
well as centroid coordinates to households.
Community workers were recruited and trained to do 
questionnaires, follow-ups, m alaria surveys (finger 
prick), and distribute treatment or placebo, as well as 
doing health prom otion among the population. Each 
community worker will be in charge of a certain num­
ber of households that they visit monthly for recording 
movement and active follow-up of malaria symptoms, 
and three monthly for finger pricking and distributing 
the treatment.
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The study is designed as a double-blind randomized 
trial with two arms. One arm is treatment with albenda­
zole (single dose of 400 mg) [32], while the other arm is 
treatment with matching placebo (both tablets from PT 
Indofarma Pharmaceutical, Bandung, Indonesia). The 
treatment is provided every three months for a period 
of two years (a total of 8 treatments) to everyone, except 
children below two years of age, pregnant women or 
severely ill persons. Computer aided block randomiza­
tion by household, using Random Allocation Software 
[33] will be assigned to the treated and placebo groups. 
The treatm ent is coded as A or B and the codes are 
concealed from investigators and patients. Labels with 
the study subject ID are printed from a computer data­
base and attached to the appropriate strip of treatment 
by a separate team located in Jakarta without the invol­
vement of the study investigators. An interim analysis 
will be performed by the monitoring committee, 1 year 
after treatment to test for any adverse effects that reten­
tion of anthelm inthic treatm ent might have on the 
growth of children and on the incidence of malaria epi­
sodes (in contrast to the hypothesis being tested). If the 
trial continues, the final unblinding of the codes will 
take place two years after treatment.
On approval of individuals in the area, peripheral 
blood will be collected from a subset of individuals over 
4 years of age that were randomly selected for whole 
blood culture based on households. The assay will be 
done at baseline, 1 and 2 years after treatm ent. For 
those who are not included in whole blood assays, 
malaria evaluation by finger pricking will be obtained 
aiming to include the whole population in the study 
area.
Every household receives a card identifying all family 
members. This card is used when community workers 
visit homes and when family members visit the Puskes- 
mas. Data on socioeconomic status and health status is 
collected at baseline and 2 years after treatment using 
questionnaires in Bahasa Indonesia. Monthly data such 
as birth, death and migration will be recorded. New­
borns and individuals who enter the study area will be 
registered with a newly assigned ID number as well as 
their geographical coordinates. Active follow-up includes 
a questionnaire with questions on clinical complaints in 
general and clinical malaria in particular and will be 
conducted monthly by community workers. In addition 
to the questionnaire, blood slides will be collected at 
three monthly intervals to test for plasmodia. For exami­
nation of intestinal helminths, stool samples will be col­
lected yearly. Samples will be used for microscopy and 
PCR analyses. Passive follow-up will be held in colla­
boration with the Puskesmas that keeps clinical records 
of individuals that visit either for consultation or for 
overnight admission, including information on diagnosis
and treatment. If malaria is suspected, two blood slides 
will be collected: one to be examined by the Puskesmas 
staff and another for re-examination by the research 
team in Jakarta at the Department of Parasitology, Uni­
versity of Indonesia (UI).
All blood samples (serum, cell pellet, plasma, and 
whole blood), blood culture supernatants, as well as 
stool samples for PCR, will be kept at -20°C in a tem ­
perature recorded freezer which is checked twice a day 
and will be sent to Jakarta on dry ice for storage -20°C 
or -80°C.
Outcomes and case definitions
The study aims to determine whether and how helminth 
infections may affect the course of infection with 
malaria parasites and disease outcome. Therefore we 
will monitor disease in individuals treated with albenda­
zole compared to placebo. The primary outcome is the 
prevalence of infection with P. falciparum  and P. vivax 
up to 2 years after treatment, the secondary outcome is 
the incidence and severity of malaria recorded as a 
result of passive and active follow-up up to 2 years after 
treatm ent. The tertiary outcome is the inflammatory 
cytokine responses to P. falciparum  antigens 1 and
2 years after treatment.
Helminth and plasmodia infections will be defined by 
the presence of parasites detected by microscopic exam­
ination of stool and blood samples respectively and will 
be confirmed by molecular (PCR-based) m ethods 
[34-38]. A malaria case is defined as an individual with 
typical malaria symptoms and a blood slide containing 
plasmodia asexual forms. Typical malaria case defini­
tions: fever (oral temperature > 37.5°C) and/or history 
of fever in the past 48 hours with a positive slide (P. 
vivax > 250/ul, P. falciparum > 1000/ul). Asymptomatic 
carriers have a blood slide positive for P. falciparum  
and/or P. vivax asexual forms, as well as positive result 
by PCR and no concomitant clinical symptoms. Sus­
pected malaria cases are defined as individuals who 
report symptoms typical of malaria but for whom no 
slide is available at the time of presentation with 
symptoms.
Parasitological examination 
Stool examination by microscopy
The Harada Mori method will be carried out on fresh 
stool samples to detect hookworm larvae. A certain 
amount of each stool sample is preserved in formalin 
(4%) and kept at room  tem perature for microscopic 
examination. The formol-ether acetate concentration 
method [39] is performed on the formalin preserved 
stool samples followed by microscopical examination for 
intestinal helm inth infections, as well as protozoan 
infections. For hookworm detection, an amount of fresh
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stool sample is incubated using filter paper soaked by 
distilled water inside sealed plastic tubes according to 
the Harada Mori method [40].
Stool examination by real-time PCR
For DNA isolation from stool, approximately 100 mg 
unpreserved faeces (that was kept at -20°C) are sus­
pended in 200 ^l PBS containing 2% polyvinylpolypyroli- 
done (PVPP; Sigma, Steinheim, Germany). DNA 
isolation and setup of the PCR reactions are performed 
using a custom-made Hamilton robot platform (made in 
Germany). After heating for 10 min at 100°C suspen­
sions are treated with sodium dodecylsulphate-protei- 
nase K for 2 h at 55°C. DNA is isolated using QIAamp 
DNA-easy 96-well plates (QIAgen, Venlo, The Nether­
lands) [36]. Within the isolation lysis buffer, 103 PFU/ml 
Phocine herpes virus 1 (PhHV-1) is added to serve as an 
internal control [41].
A. duodenale, N. americanus (hookworm), A. lumbricoides,
S. stercoralis real-time PCR (ANAS-PCR) [or just "helminth 
rt-PCR"]
Sequences of the A. duodenale-, N. americanus-, and S. 
stercoralis-specific  prim ers and probes are used as 
described previously [37,38] with some modifications in 
fluorophore- and quencher-chemistry. M inor groove 
binding (MGB) probes are replaced by XS probes (Biole- 
gio, Malden, The Netherlands) and to accommodate the 
specific fluorophor combination of the CFX real-time 
PCR system (Bio-Rad laboratories, USA) the A. duode­
nale specific XS-probe is labelled with Texas Red and the 
S. stercoralis-specific probe is labelled with Quasar-705. 
The A. lumbricoides-specific primers and probe are cho­
sen using Primer Express software (Applied Biosystems, 
Foster City, CA), from the internal transcribed-spacer-1 
(ITS1) sequence of A. lumbricoides (GenBank accession 
ALJ000895). The A. lum bricoides-specific primers, 
Alum96F 5’-GTAATAGCAGTCGGCGGTTTCTT-3’ 
and Alum183R 5’-GCCCAACATGCCACCTATTC-3’ 
amplify an 87-bp fragment of the ITS1 sequence and the 
XS-probe Alum124T Yakima Yellow-5’-TTGGCGGA- 
CAATTGCATGCGAT-3’-XS is used to detect the A. 
lumbricoides-specific product. The real-time PCRs were 
optimized first as monoplex assays with 10-fold dilution 
series of A. duodenale, N. americanus, A. lumbricoides, 
and S. stercoralis DNA, respectively. The monoplex real­
time PCRs were thereafter compared with the multiplex 
PCR with the PhHV internal control. The cycle threshold 
(Ct) values obtained from testing the dilution series of 
each pathogen in both the individual assay and the multi­
plex assay were similar, and the same analytical sensitivity 
was achieved. The multiplex ANAS PCR showed 100% 
specificity when tested against 145 DNA controls derived 
from a wide range of intestinal microorganisms [35].
Amplification reactions are performed in white PCR 
plates in a volume of 25 ^l with PCR buffer (HotstarTaq
m aster mix, QIAgen, Germany), 5 mM MgCl2, 2.5 
^gram Bovine Serum Albumin (Roche Diagnostics 
Nederland B.V., Almere, the Netherlands), 5 pmol of 
each A. duodenale-specific primer, and of each N. amer- 
icanus-specific primer, 2 pmol of each A. lumbricoides- 
specific primer, 2.5 pmol of each S. stercoralis-specific 
primer and 3.75 pmol of each PhHV-1-specific primer, 
1.25 pmol of each N. americanus-specific XS-probe, A. 
lumbricoides-specific XS-probe, S. stercoralis-specific 
double-labelled probe, and PhHV-1-specific double­
labelled probe, and 2.5 pmol of the A. duodenale-speci- 
fic XS-probe, and 5 ^l of the DNA sample.
Amplification consists of 15 min at 95°C followed by 50 
cycles of 15 s at 95°C, 30 s at 60°C, and 30 s at 72°C. 
Amplification, detection, and analysis are performed with 
the CFX real-time detection system (Bio-Rad laboratories). 
The PCR output from this system consists of a cycle- 
threshold (Ct) value, representing the amplification cycle 
in which the level of fluorescent signal exceeds the back­
ground fluorescence, and reflecting the parasite-specific 
DNA load in the sample tested. Negative and positive con­
trol samples are included in each amplification run.
The amplification is considered to be hampered by 
faecal inhibitory factors if the expected cycle threshold 
(Ct) value of 33 in the PhHV-specific PCR is increased 
by more than 3.3 cycles.
Blood examination by microscopy
To detect P. falciparum , P. vivax, P. malariae, and P. 
ovale , blood slides (thick and thin) are stained with 
Giemsa [42] followed by microscopic examination [43]. 
Blood examination by real-time PCR 
DNA was isolated from 200 ^l blood with QIAamp 
DNA-easy 96-well plates according to the m anufac­
turer's recommendations. DNA isolation and setup of 
the PCR reactions are performed using a custom-made 
Hamilton robot platform.
P. falciparum, P. vivax, P. ovale, and P. malariae (malaria) 
real-time PCR
Sequences of the Plasmodium -specific primers and the 
P. falciparum, P. vivax, P. ovale, and P. malariae-speci- 
fic probes are used as described previously[34,44] with 
some modifications in the fluorophore- and quencher- 
chemistry. M inor groove binding (MGB) probes are 
replaced by XS probes and to accommodate the specific 
fluorophor combination of the CFX system the P. falci­
parum -specific XS-probe is labelled with Yakima Yellow, 
the P. ovale-specific XS-probe is labelled with Texas Red 
and the P. malariae-specific probe is labelled with Qua­
sar-705. An additional P. ovale-type 2 XS-probe (Texas 
Red 5'-TCCAAAAGGAATTTTCTTATT-3'-XSQ) is 
used for sensitive detection of the P. ovale genetic var­
iant type 2 (GenBank accession X99790/J001527).
Amplification reactions of each DNA sample are per­
formed in white PCR plates, in a volume of 25 ^l with
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PCR buffer (HotstarTaq master mix), 5 mmol/l MgCl2, 
12.5 pmol of each Plasmodium-specific prim er and 
15 pmol of each PhHV-1-specific primer, 1.5 pmol of each 
P. falciparum, P. vivax-, P. malariae-specific XS-probes, 
and PhHV-1-specific Cy5 double-labelled detection probe, 
and 2.5 pmol of each P. ovale-specific XS-probes (Biole- 
gio), and 5 ^l of the DNA sample were used.
Amplification, detection, and analysis are performed as 
described for the faecal PCR.
Immunological Measurements
Whole blood culture and cytokine measurements
Blood samples (6 ml) are drawn into Vacutainers (BD, 
Franklin Lakes, NJ, USA) containing sodium heparin as 
anticoagulant. Within 6 hours, blood cultures are set up 
according to methods that were optimized and tested 
under field conditions during pilot studies. The hepari- 
nized blood is diluted 1:4 with RPMI 1640 medium 
(Invitrogen, Breda, The Netherlands) (supplemented 
with 2 mM glutamate, 1 mM pyruvate, 100 IU penicillin 
and 100 ^g/ml streptomycin) and cultured in 96 well 
round bottomed plates in 37°C with 5% CO2. Stimula­
tions were performed with medium/control, PHA (2 ^g/ 
ml, Wellcome Diagnostics, Darford, UK), LPS (1 ng/ml 
Sigma-Aldrich, Zwijndrecht, The Netherlands), Pam3Cys 
(100 ng/ml, Cayla-InvivoGen Europe, Toulouse, France), 
PolyIC (50 ^g/ml, Cayla-InvivoGen Europe, Toulouse, 
France), Ascaris antigen (20 ^g/ml, as prepared by van 
Riet E et al [45]), iRBC (1 x 106, prepared by Radboud 
University Nijmegen Medical Centre, Nijmegen, The 
Netherlands[46]), uRBC (1 x 106, prepared by Radboud 
University Nijmegen Medical Centre, Nijmegen, The 
Netherlands [46]). Supernatants are collected on day 1 
(unstimulated control, LPS, Pam3Cys) and day 3 (unsti­
mulated control, PHA, Ascaris, iRBC, uRBC, PolyIC). 
Cytokine concentrations in supernatants are assessed by 
means of immunobead-based multiplex assays. This is 
an assay that permits simultaneous quantification of 
multiple cytokines in a small sample volume. Panels of 
capture antibody-coated beads and labeled detection 
antibodies are purchased from Bio Source (Camarillo, 
California, USA). The cytokines measured will represent 
pro- and anti-inflammatory, Th1 and Th2 cytokines: 
TNF-a and IL-10 from day 1 supernatants as well as IL- 
2, IL-5, IL-10, IFN-g, and TNF-a for day 3 supernatants. 
Analysis will be performed on a Liquichip 200® W ork­
station (Qiagen, Venlo, The Netherlands) using Liqui- 
chip analyzer software (Qiagen, Venlo, The 
Netherlands).
Total IgE
Total IgE will be measured as described previously [47]. 
Briefly, maxisorp plates (Thermo Fisher Scientific, Ros- 
kilde, Denmark) are coated overnight with 100 ^l/well 
rabbit anti-human IgE (Dako, Glostrup, Denmark) at 1/
1400 dilution in 0.1 M carbonate buffer. Plates are 
blocked with 100 ^l/well phosphate buffered saline 
(PBS) containing 5% bovine serum albumin (BSA, Albu­
min Fraction V, Boehringer, Mannheim, Germany). Sera 
to be tested are diluted 1:200 in PBS containing 5% fetal 
calf serum (FCS, Greiner Bio-One, Alphen a/d Rijn, 
Netherlands). A positive standard serum  containing 
human IgE (NIBSC, Potters Bar, UK) is diluted down 1/3 
in a series from 90 IU /m l until a final concentration 
0.12 IU/ml on each plate and incubated for 1 hour at 
room temperature. After washing step, IgE biotinylated 
goat anti-human IgE antibody (1/1000 (Vector Labora­
tories, Burlingame, CA, USA)) is added followed by 
Streptavidin Alkaline Phosphatase conjugate (1/3000 
(Boehringer, Mannheim, Germany)). The colour is devel­
oped by addition of para-nitrophenylphosphate substrate 
(p-NPP (Boehringer, M annheim, Germany)) diluted 
in diethanolamine buffer (DEA, 0.5 mM Mg CL2, 0.1 
M DEA, pH 9.6 (Merck, Darmstadt, Germany) and opti­
cal density is measured at 405 nm.
Statistical analyses
A database using MS Access is developed for this study. 
At baseline, we will analyze whether helminth infected 
subjects are at a higher risk of having P. falciparum  or 
P. vivax infections in terms of presence of infection and 
intensity. The effect of anthelminthic treatment will be 
assessed 1 and 2 years after treatment by analyzing the 
prevalence ratios as well as the incidence ratios of 
malaria infection (clinical cases and parasitemia). In 
addition, treatment will be compared with placebo for 
reduction of helm inth infection and is based on an 
intention to treat principle, in anticipation of individual 
movement between treatment groups. Cytokine profiles 
in response to parasite antigens will be analyzed for 
levels of pro- and anti-inflammatory cytokines.
The characterization of immune responses to hel­
minth infections, malaria infections and co-infections 
will be assessed prior to treatment using linear regres­
sion [48]. As cytokine levels are non-normally distribu­
ted, we will use log-transformed cytokine data for all 
analyses regarding effect of helminth treatment on cyto­
kine profile and susceptibility to plasmodium infection. 
For these analyses, multilevel modeling will be used and 
the use of longitudinal data will take into account 
repeated measurements [48]. Any bias related to selec­
tion of participants and outcome of treatm ent will be 
assessed by comparing individuals that are lost to fol­
low-up and individuals that are not lost and will be 
compared on the basis of their baseline characteristics, 
age, gender, village, and socioeconomic status and para­
sitic infections. A similar assessment will also be under­
taken to compare the characteristics of individuals in 
the treatment and placebo groups at inclusion into the
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study. Chi-square analyses will be used to test 
proportions.
Multiple regression analysis will be used to determine 
1) the association between helminth infections (either all 
helminths or individual species) with malaria parasites 
(either all or individual species); 2) the effect of decreas­
ing helminth infection on plasmodia parasitaemia and 
incidence of malaria cases and 3) the effect of decreas­
ing helminth infection on immunological responses to 
malaria antigen. All analyses will be adjusted for con- 
founders such as socioeconomic status, body mass 
index, age and sex. During the study any other confoun- 
ders that are identified will be used in our analyses.
Power calculation
Unpublished microscopy data from the area showed the 
combined prevalence of P. falciparum  and P. vivax was 
12% in the target population and the helminth infection 
(A. lumbricoides, Hookworm, T. trichiura) in the popu­
lation was 60%. As study activities such as active follow- 
up and prompt treatment will have an effect on the pre­
valence, we expect the malaria prevalence to decrease to 
an estimated 6%. Based on these findings a power calcu­
lation (given an alpha of 0.05 and a power of 0.80) gave 
a sample size of 749 study subjects needed, in order to 
detect a 50% reduction or increase in the prevalence of 
plasmodia after 2 years of anthelminthic treatment. The 
effect of treatment will presumably be present in hel­
minth carriers only and as an estimated 60% will be car­
riers of helm inths during study period, giving an 
estim ated 1248 subjects in each study arm will be 
needed. Allowing for an estimated 20% lost to follow-up 
due to movement and refusal, we would need to include 
1495 participants in each arm.
Ethical consideration and trial registration, information, 
recruitment and consent
This study was approved by The Ethical Committee of 
Faculty of Medicine, University of Indonesia, ref: 194/ 
PT02.FK/Etik/2006 and registered as clinical trial ref: 
ISRCTN83830814 and has been filed by ethics commit­
tee of the Leiden University Medical Center. The study 
is reported in accordance with the CONSORT guide­
lines for cluster-randomized studies [49].
The regional health authorities in Ende, the regional 
capital, were informed of the study and gave their agree­
ment and support. Socialization took place over a two 
year period prior to the study involving staff at the pub­
lic health centre (Puskesmas) and 50 community work­
ers, including training for follow-up of study subjects 
keeping the community well-informed and well-engaged. 
Through many organized sessions, the village heads 
were involved in passing on inform ation about the 
study, including the benefits and risks involved. The
longitudinal nature was explained and inform ation 
sheets and consent forms (in Bahasa Indonesia) were 
distributed. Inhabitants of the area were invited to parti­
cipate in the study, consented either by written signa­
ture or thumb print and were informed that they may 
withdraw from the study at any time, for any reason 
and without consequences. For children below 15 years 
old of age also parent consent was obtained. Probable 
illness by burden of helminth infection will be taken 
into account by three study doctors that will be present 
in the area as well as by collaboration with the Puskes- 
mas. Severe cases will be treated directly. The medical 
doctors will also give support and treatment to the Pus- 
kesmas. After completion of the study the whole popu­
lation will be adequately treated for helminth infections 
[32,50].
Description of the population recruited
The study has so far provided data that are shown in a 
flow chart given in Figure 2. During registration (Janu­
ary 2007 - April 2008) a total of 4650 individuals were 
registered in 753 households. At baseline in (April 2008) 
3854 of the registered population are residing in the vil­
lage in 734 household. For the immunological studies 
250 households were randomly selected within 734 
registered households, to allow for 1065 eligible indivi­
duals (Figure 2).
Table 1 shows age-stratified migration patterns. Most 
m igration is for seeking employment or education 
opportunities and most are male. The median age of the 
residents is 20 years while this is 19 for those who move 
out of the area. The age pyramid is shown in Figure 3 
and is typical for low to middle income countries [51].
The traditional source of income in the area is farm­
ing and fishing while some individuals engage in jobs at 
government offices with a few in the private sector (Fig­
ure 4). The education level of the majority over 15 years 
of age is elementary school (40.6%) followed by senior 
high school (27,2%), and junior high school (18.9%) 
while 5.4% has college or University degrees. Around 
5.5% is illiterate, either not educated at all or dropped 
out from elementary school (Figure 5).
Discussion
Since this large comm unity-based trial provides an 
important possibility to undertake a series of evaluations 
on the effect of helminth infections on malaria as well 
as the control of helminth and malaria at the commu­
nity level, our study could help develop evidence-based 
policymaking. This study is unique in that it will provide 
data on anthelminthic treatment efficacy and effective­
ness in a defined large population in a developing coun­
try. In conclusion the ImmunoSPIN helminth-malaria 
study is the first and currently the only longitudinal
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#  Three monthly treatment with a lbendazole  In population above 2 yrs old 
F ig u re  2 Profile o f the Im m unoSPIN-M alaria sub  project http://immunospin.org
Table 1 Age distribution of the study population who have stayed or moved out of the study area in 16 months of 
period*
A g e  gro up  
(years)
Staying Moved
Male 
(n =  1740)
Fem ale (n =  2087) Total (n =  3827) M ale (n =  431) Fem ale (n =  365) Total (n =  796)
0-4 175 (10%) 221 (10.6%) 396 (10.3%) 10 (2.3%) 11 (3%) 21 (2.6%)
5-14 491 (28.2%) 467 (22.4%) 958 (25%) 49 (11.4%) 47 (12.9%) 96 (12.1%)
15-24 353 (20.3%) 412 (19.7%) 765 (20%) 248 (57.5%) 224 (61.4%) 472 (59.3%)
25-34 191 (11%) 305 (14.6%) 496 (13%) 71 (16.5%) 53 (14.5%) 124 (15.6%)
35-44 207 (11.9%) 284 (13.6%) 491 (12.8%) 37 (8.6%) 15 (4.1%) 52 (6.5%)
45-54 160 (9.2%) 198 (9.5%) 358 (9.4%) 8 (1.8%) 8 (2.2%) 16 (2%)
55-64 94 (5,4%) 119 (5.7%) 213 (5.6%) 2 (0.5%) 3 (0.9%) 5 (0.6%)
56II
A 69 (4%) 81 (3.9%) 150 (3.9%) 6 (1.4%) 4 (1%) 10 (1.3%)
* Data from 4623 of 4650, because 27 individuals was not known for their age or birthday.
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43; 1°/5 36; 5%
F ig u re  4  Jo b  distribution. At baseline, profession was assessed for everyone above 15 years of age in the study area (n =  2961).
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559; 19%
F ig u re  5 Education level. At baseline, education was assessed for everyone above 15 years of age in the study area (n =  2961).
study of helminth and malaria co-infections in Indone­
sia. The study has received enthusiastic support from 
the authorities in Ende. At the same time, the study 
facilitates the transfer of state of the art technologies in 
immunology, molecular biology, epidemiology and sta­
tistics to Indonesia.
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